The binding interactions between immobilized antibodies and EVs isolated from different cancer cell lines revealed a unique SPR molecular fingerprint (SPR-MFP) consisting of varying expression levels of the CD9, CD63 and CD81 EV biomarkers, as well as CXCR4. This evidence concerns the gene CD63 and cancer.